Associate Professor Kerrie McDonald

Jue TR; Olafson LR; Siddell AH; Rapkins RW; Ng B; Yin JXM; Lu VM; Chung SA; Whittaker SP; Davies M; Fairhall JM; Hovey EJ; McDonald KL, 2019, 'A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype', Cold Spring Harbor Molecular Case Studies, vol. 5, http://dx.doi.org/10.1101/mcs.a003251

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS, 2018, 'Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer', Cancer Biology and Therapy, vol. 19, pp. 1078 - 1087, http://dx.doi.org/10.1080/15384047.2018.1491498

Lu VM; Texakalidis P; McDonald KL; Mekary RA; Smith TR, 2018, 'The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis', Clinical Neurology and Neurosurgery, vol. 174, pp. 149 - 155, http://dx.doi.org/10.1016/j.clineuro.2018.09.019

Lu VM; Phan K; Yin JXM; McDonald KL, 2018, 'Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature', Journal of Neuro-Oncology, vol. 139, pp. 231 - 238, http://dx.doi.org/10.1007/s11060-018-2897-2

Lu VM; Goyal A; Vaughan LS; McDonald KL, 2018, 'The impact of hyperglycemia on survival in glioblastoma: A systematic review and meta-analysis', Clinical Neurology and Neurosurgery, vol. 170, pp. 165 - 169, http://dx.doi.org/10.1016/j.clineuro.2018.05.020

Lu VM; Jue TR; McDonald KL; Rovin RA, 2018, 'The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis', World Neurosurgery, vol. 115, pp. 453 - 459.e3, http://dx.doi.org/10.1016/j.wneu.2018.04.016

de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H, 2018, 'A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence', Cell Reports, vol. 23, pp. 637 - 651, http://dx.doi.org/10.1016/j.celrep.2018.03.107

Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P, 2018, 'Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis', World Neurosurgery, vol. 111, pp. e539 - e545, http://dx.doi.org/10.1016/j.wneu.2017.12.112

Felthun J; Reddy R; McDonald KL, 2018, 'How immunotherapies are targeting the glioblastoma immune environment', Journal of Clinical Neuroscience, vol. 47, pp. 20 - 27, http://dx.doi.org/10.1016/j.jocn.2017.10.019

Lu VM; Jue TR; Phan K; McDonald KL, 2018, 'Quantifying the prognostic significance in glioblastoma of seizure history at initial presentation: A systematic review and meta-analysis', Clinical Neurology and Neurosurgery, vol. 164, pp. 75 - 80, http://dx.doi.org/10.1016/j.clineuro.2017.11.015

Jue TR; Sena ES; Macleod MR; McDonald KL; Hirst TC, 2018, 'A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models', Oncotarget, vol. 9, pp. 11387 - 11401, http://dx.doi.org/10.18632/oncotarget.24334

Lu VM; McDonald KL, 2018, 'Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma', CNS oncology, vol. 7, pp. 41 - 50, http://dx.doi.org/10.2217/cns-2017-0019

Lu VM; McDonald KL; Townley HE, 2017, 'Realizing the therapeutic potential of rare earth elements in designing nanoparticles to target and treat glioblastoma', Nanomedicine, vol. 12, pp. 2389 - 2401, http://dx.doi.org/10.2217/nnm-2017-0193

Lu VM; McDonald KL, 2017, 'The current evidence of statin use affecting glioblastoma prognosis', Journal of Clinical Neuroscience, vol. 42, pp. 196 - 197, http://dx.doi.org/10.1016/j.jocn.2017.04.036

Sinnadurai M; McDonald KL, 2017, 'Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma', Journal of Neuro-Oncology, vol. 132, pp. 359 - 372, http://dx.doi.org/10.1007/s11060-017-2390-3

Nalkiran HS; McDonald KL, 2017, 'Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?', Journal of Cancer Research and Therapeutics, vol. 13, pp. 329 - 336, http://dx.doi.org/10.4103/0973-1482.188438

Jue TR; Nozue K; Lester AJ; Joshi S; Schroder LBW; Whittaker SP; Nixdorf S; Rapkins RW; Khasraw M; McDonald KL, 2017, 'Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma', Journal of Translational Medicine, vol. 15, http://dx.doi.org/10.1186/s12967-017-1164-1

Lester A; Rapkins R; Nixdorf S; Khasraw M; McDonald K, 2017, 'Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?', Clinical and Translational Oncology, vol. 19, pp. 273 - 278, http://dx.doi.org/10.1007/s12094-016-1547-4

Greenall SA; Lim YC; Mitchell CB; Ensbey KS; Stringer BW; Wilding AL; O'Neill GM; McDonald KL; Gough DJ; Day BW; Johns TG, 2017, 'Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma', Oncogenesis, vol. 6, http://dx.doi.org/10.1038/oncsis.2017.33

Jue TR; McDonald KL, 2016, 'The challenges associated with molecular targeted therapies for glioblastoma', Journal of Neuro-Oncology, vol. 127, pp. 427 - 434, http://dx.doi.org/10.1007/s11060-016-2080-6

Hau E; Shen H; Clark C; Graham PH; Koh ES; L Mcdonald K, 2016, 'The evolving roles and controversies of radiotherapy in the treatment of glioblastoma', Journal of Medical Radiation Sciences, vol. 63, pp. 114 - 123, http://dx.doi.org/10.1002/jmrs.149

Shen H; Hau E; Joshi S; Dilda PJ; McDonald KL, 2015, 'Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism', Molecular Cancer Therapeutics, vol. 14, pp. 1794 - 1804, http://dx.doi.org/10.1158/1535-7163.MCT-15-0247

Shen H; Decollogne S; Dilda P; Hau E; Chung S; Luk P; Hogg PJ; McDonald KL, 2015, 'Dual-targeting of aberrant glucose metabolism in glioblastoma', Journal of Experimental & Clinical Cancer Research, vol. 34, http://dx.doi.org/10.1186/s13046-015-0130-0

McDonald KL; Tabone T; Nowak AK; Erber WN, 2015, 'Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation', Oncology Letters, vol. 9, pp. 2063 - 2067, http://dx.doi.org/10.3892/ol.2015.2980

Mallawaaratchy DM; Buckland ME; McDonald KL; Li CCY; Ly L; Sykes EK; Christopherson RI; Kaufman KL, 2015, 'Membrane Proteome Analysis of Glioblastoma Cell Invasion', Journal of Neuropathology and Experimental Neurology, vol. 74, pp. 425 - 441, http://dx.doi.org/10.1097/NEN.0000000000000187

Schröder LBW; McDonald KL, 2015, 'CDK4/6 inhibitor PD0332991 in glioblastoma treatment: Does it have a future?', Frontiers in Oncology, vol. 5, http://dx.doi.org/10.3389/fonc.2015.00259

Rapkins RW; Wang F; Nguyen HTN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL, 2015, 'The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide', Neuro-Oncology, vol. 17, pp. 1589 - 1598, http://dx.doi.org/10.1093/neuonc/nov064

Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ, 2014, 'Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology', PLOS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0112945

Damodaran O; Van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G, 2014, 'Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy', Journal of Clinical Neuroscience, vol. 21, pp. 478 - 481, http://dx.doi.org/10.1016/j.jocn.2013.07.042

Tabone T; Abuhusain HJ; Nowak AK; Erber WN; McDonald KL, 2014, 'Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study', Journal of Clinical Pathology, vol. 67, pp. 550 - 555, http://dx.doi.org/10.1136/jclinpath-2014-202173

Tivnan A; Zhao J; Johns TG; Day BW; Stringer BW; Boyd AW; Tiwari S; Giles KM; Teo C; McDonald KL, 2014, 'The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma', Tumor Biology, vol. 35, pp. 1459 - 1465, http://dx.doi.org/10.1007/s13277-013-1200-6

Jue TR; Hovey E; Davis S; Carleton O; McDonald KL, 2014, 'Incorporation of biomarkers in phase II studies of recurrent glioblastoma', Tumor Biology, vol. 36, pp. 153 - 162, http://dx.doi.org/10.1007/s13277-014-2960-3

Ohta T; Kim YH; Oh JE; Satomi K; Nonoguchi N; Keyvani K; Pierscianek D; Sure U; Mittelbronn M; Paulus W; Vital A; Yokoo H; McDonald K; Kleihues P; Nazaret N; Barbet F; Lachuer J; Ohgaki H, 2014, 'Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas', Journal of Neuropathology and Experimental Neurology, vol. 73, pp. 908 - 915, http://dx.doi.org/10.1097/NEN.0000000000000110

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, vol. 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Yeung YT; McDonald KL; Grewal T; Munoz L, 2013, 'Interleukins in glioblastoma pathophysiology: Implications for therapy', British Journal of Pharmacology, vol. 168, pp. 591 - 606, http://dx.doi.org/10.1111/bph.12008

Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME, 2013, 'A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care', Oncotarget, vol. 4, pp. 502 - 530, http://dx.doi.org/10.18632/oncotarget.969

Tivnan A; McDonald KL, 2013, 'Current progress for the use of miRNAs in glioblastoma treatment', Molecular Neurobiology, vol. 48, pp. 757 - 768, http://dx.doi.org/10.1007/s12035-013-8464-0

McDonald K; Aw G; Kleihues P, 2013, 'Role of biomarkers in the clinical management of glioblastomas: What are the barriers and how can we overcome them?', Frontiers in Neurology, vol. 3, pp. Article number 188, http://dx.doi.org/10.3389/fneur.2012.00188

Yeung Y; Bryce N; Adams S; Braidy N; Koyanagi M; McDonald K; Teo C; Watterson D; Guillemin GJ; Grewal T; Munoz L, 2012, 'p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and invasiveness of human glioblastoma cells', Journal of Neuro-Oncology, vol. 109, pp. 35 - 44, http://dx.doi.org/10.1007/s11060-012-0875-7

Wong JWH; Abuhusain H; McDonald K; Don AS, 2012, 'MMSAT: Automated Quantification of Metabolites in Selected Reaction Monitoring Experiments', Analytical Chemistry, vol. 84, pp. 470 - 474, http://dx.doi.org/10.1021/ac2026578

McDonald KL, 2011, 'DRIVING A MOTOR VEHICLE AFTER DIAGNOSIS OF A BRAIN TUMOR: A PRIVILEGE, NOT A RIGHT', NEURO-ONCOLOGY, vol. 13, pp. 125 - 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600495&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Abuhusain HJ; McDonald KL; Don AS, 2011, 'HIGH-THROUGHPUT LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MEASUREMENTS OF BIOACTIVE LIPIDS INTEGRATED WITH GENE EXPRESSION DATA IN GLIOBLASTOMA', NEURO-ONCOLOGY, vol. 13, pp. 81 - 81, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600328&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sevim H; Chung L; Wheeler HT; Baxter RC; McDonald KL, 2011, 'ABERRANT EXPRESSION OF LOW-MOLECULAR-WEIGHT PROTEINS ASSOCIATED WITH RESPONSE TO CONVENTIONAL CONCURRENT CHEMORADIOTHERAPY TREATMENT', NEURO-ONCOLOGY, vol. 13, pp. 79 - 80, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu D; Mreich E; Chung S; Teo C; Wheeler H; McDonald KL, 2011, 'MGMT PROMOTER METHYLATION AND DNA MISMATCH REPAIR IN PRIMARY AND RELAPSED GLIOBLASTOMA', NEURO-ONCOLOGY, vol. 13, pp. 16 - 17, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fowler A; Thomson D; Giles KM; Maleki S; Mreich E; Wheeler H; Leedman P; Biggs MT; Cook R; Little N; Robinson BG; McDonald K, 2011, 'MiR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion', European Journal of Cancer, vol. 47, pp. 953 - 963, http://dx.doi.org/10.1016/j.ejca.2010.11.026

Sevim H; Parkinson J; McDonald K, 2011, 'Etoposide-mediated glioblastoma cell death: Dependent or independent on the expression of its target, topoisomerase II alpha?', Journal of Cancer Research and Clinical Oncology, vol. 137, pp. 1705 - 1712, http://dx.doi.org/10.1007/s00432-011-1046-5

Chung SA; Dilda PJ; Ramsay EE; Teo C; Hogg PJ; McDonald KL, 2011, 'PENAO: A novel tumor metabolism inhibitor for glioblastoma', CANCER RESEARCH, vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-2604

McDonald KL; McDonnell J; Muntoni A; Henson JD; Hegi ME; Von Deimling A; Wheeler HR; Cook RJ; Biggs MT; Little NS; Robinson BG; Reddel RR; Royds JA, 2010, 'Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival', Journal of Neuropathology and Experimental Neurology, vol. 69, pp. 729 - 736, http://dx.doi.org/10.1097/NEN.0b013e3181e576cf

Duncan CG; Killela PJ; Payne CA; Lampson B; Chen WC; Liu J; Solomon D; Waldman T; Towers AJ; Gregory SG; McDonald K; McLendon RE; Bigner DD; Yan H, 2010, 'Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes', Oncotarget, vol. 1, pp. 265 - 277, http://dx.doi.org/10.18632/oncotarget.137

Elston MS; Gill AJ; Conaglen JV; Clarkson A; Cook RJ; Little NS; Robinson BG; Clifton-Bligh RJ; McDonald KL, 2009, 'Nuclear accumulation of E-Cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas', Journal of Clinical Endocrinology and Metabolism, vol. 94, pp. 1436 - 1442, http://dx.doi.org/10.1210/jc.2008-2075

Soon PSH; Gill AM; Benn D; Clarkson A; Robinson B; Mcdonald K; Sidhu S, 2009, 'Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas', Endocrine - Related Cancer, vol. 16, pp. 573 - 583, http://dx.doi.org/10.1677/ERC-08-0237

McCormack A; McDonald K; Gill A; Clark SJ; Burt MG; Campbell K; Braund W; Little N; Cook R; Grossman AB; Robinson BG; Clifton-Bligh R, 2009, 'Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours', Clinical Endocrinology, vol. 71, pp. 226 - 233, http://dx.doi.org/10.1111/j.1365-2265.2008.03487.x

Payne CA; Maleki S; Messina M; O'Sullivan MG; Stone G; Hall NR; Parkinson JF; Wheeler HR; Cook RJ; Biggs MT; Little NS; Teo C; Robinson BG; McDonald KL, 2008, 'Loss of prostaglandin D2 synthase: A key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma', Molecular Cancer Therapeutics, vol. 7, pp. 3420 - 3428, http://dx.doi.org/10.1158/1535-7163.MCT-08-0629

Elston MS; Gill AJ; Conaglen JV; Clarkson A; Shaw JM; Law AJJ; Cook RJ; Little NS; Clifton-Bligh RJ; Robinson BG; McDonald KL, 2008, 'Wnt pathway inhibitors are strongly down-regulated in pituitary tumors', Endocrinology, vol. 149, pp. 1235 - 1242, http://dx.doi.org/10.1210/en.2007-0542

Soon PSH; Mcdonald K; Robinson B; Sidhu S, 2008, 'Molecular markers and the pathogenesis of adrenocortical cancer.', Journal of Clinical Oncology, vol. 13, pp. 548 - 561, http://dx.doi.org/10.1634/theoncologist.2007-0243

Soon PSH; Libe R; Benn D; Gill A; Shaw J; Sywak M; Groussin L; Bertagna X; Gicquel C; Bertherat J; Mcdonald K; Sidhu S; Robinson B, 2008, 'Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B in the pathogenesis of adrenocortical tumors.', Annals of Thoracic Surgery, vol. 247, pp. 157 - 164, http://dx.doi.org/10.1097/SLA.0b013e318153ff55

Au A; McDonald K; Gill AM; Sywak M; Diamond T; Conigrave A; Clifton-Bligh R, 2008, 'PTH mutation with primary hyperparathyroidism and undetectable intact PTH', New England Journal of Medicine, vol. 359, pp. 1184 - 1186, http://dx.doi.org/10.1056/NEJMc0802570

McDonald KL; O'Sullivan MG; Parkinson JF; Shaw JM; Payne CA; Brewer JM; Young L; Reader DJ; Wheeler HT; Cook RJ; Biggs MT; Little NS; Teo C; Stone G; Robinson BG, 2007, 'IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients', Journal of Neuropathology and Experimental Neurology, vol. 66, pp. 405 - 417, http://dx.doi.org/10.1097/nen.0b013e31804567d7

Kaufman KL; Ly L; McKay M; Mallawaaratchy DM; Mactier S; Crossett B; Molloy M; Buckland ME; McDonald KL; Christopherson RI, 2014, 'COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Turin, ITALY, presented at 11th Congress of the European-Association-of-Neuro-Oncology, Turin, ITALY, 09 October 2014 - 12 October 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344235700377&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

McDonald KL; Ha W; Sevim H, 2014, 'MIF-CD74 GUIDED THERAPEUTIC STRATEGY FOR THE UPFRONT TREATMENT OF GBM PATIENTS WITH AN UNMETHYLATED MGMT PROMOTER', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, presented at 20th International Conference on Brain Tumor Research and Therapy, CA, 20 July 2014 - 22 July 2014, http://dx.doi.org/10.1093/neuonc/nou206.15

Nozue-Okada K; Nagane M; McDonald KL, 2013, 'COMBINING PARP INHIBITORS WITH TMZ: IMPROVED EFFICACY OBSERVED IN RECURRENT PATIENT-DERIVED CELL LINES COMPARED TO PRIMARY CELLS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, San Francisco, CA, pp. 54 - 54, presented at 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO), San Francisco, CA, 21 November 2013 - 24 November 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000327456200226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shen H; Luk PP; Chung SA; Decollogne S; Dilda PJ; Hogg PJ; McDonald KL, 2013, 'PENAO, a novel mitochondria-targeted agent, has shown potent antitumor effect on glioblastoma in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-1701